GlassScriptPhysician profile
Thomas B De Miranda
NPI 1689866725
$4,000.39
in general payments reported to CMS, 2019-2025
17 companies · $866 in 2025
The $866 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $81.51 · 2024: $2,899 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,141 · Food and Beverage: $1,264 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,140.73 |
| Food and Beverage | $1,264.21 |
| Education | $360.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,260.24 | 2024 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Tersera Therapeutics LLC | $584.21 | 2024-2025 | Prialt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.77 | 2019-2025 | Relistor |
| Averitas Pharma INC. | $247.18 | 2024-2025 | Qutenza |
| Gilead Sciences, INC. | $145.09 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $105.18 | 2024-2025 | Belbuca, Xtampza |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Valinor Pharma, LLC | $40.67 | 2025 | Movantik |
| Genentech USA, INC. | $30.28 | 2019 | |
| Saluda Medical Americas, INC. | $30.00 | 2024 | Evoke |
| Spr Therapeutics, INC | $28.43 | 2024 | Sprint Pns System |
| Boston Scientific Corporation | $26.49 | 2024 | |
| Abbvie INC. | $25.65 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $22.64 | 2025 | |
| Bioventus LLC | $16.85 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas De Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.